Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Modified Response Evaluation Criteria in Solid Tumors (mRECIST)

    Measures treatment response, specifically to cytotoxic drugs, based on tumor shrinkage.
    Favorite

    BEFORE USE

    Use in liver lesions meeting the following criteria:

    • Can be accurately measured in at least one dimension as 10 mm or more (measure longest diameter).
    • Suitable for repeat measurement.
    • Intratumoral arterial enhancement on contrast-enhanced CT or MRI.
    When to Use
    Pearls/Pitfalls
    Why Use
    mm
    mm

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights

    Advice

    • Contrast-enhanced CT or MRI is the imaging modality of choice for evaluating lesions.
    • European Association for the Study of the Liver (EASL) guidelines recommend evaluating for mRECIST criteria 1 month after undergoing treatment (surgery, locoregional therapy or initiation of systemic chemotherapy).

    Management

    recist treatment hcc
     
    CR, complete response. PR, partial response. SD, stable disease. PD, progressive disease. IR, incomplete response.